Join Growin Stock Community!

Ventyx biosciences, inc.VTYX.US Overview

US StockHealthcare
(No presentation for VTYX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VTYX AI Insights

VTYX Overall Performance

VTYX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VTYX Recent Performance

0.04%

Ventyx biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

VTYX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VTYX Key Information

VTYX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VTYX Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Price of VTYX

VTYX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VTYX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.24
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.24
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is VTYX's latest earnings report released?

    The most recent financial report for Ventyx biosciences, inc. (VTYX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VTYX's short-term business performance and financial health. For the latest updates on VTYX's earnings releases, visit this page regularly.

  • How much debt does VTYX have?

    As of the end of the reporting period, Ventyx biosciences, inc. (VTYX) had total debt of 10.02M, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does VTYX have?

    At the end of the period, Ventyx biosciences, inc. (VTYX) held Total Cash and Cash Equivalents of 32.95M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VTYX's EPS continuing to grow?

    According to the past four quarterly reports, Ventyx biosciences, inc. (VTYX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VTYX?

    Ventyx biosciences, inc. (VTYX)'s Free Cash Flow (FCF) for the period is -17.56M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 50.49% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VTYX?

    The latest valuation data shows Ventyx biosciences, inc. (VTYX) has a Price-To-Earnings (PE) ratio of -6.2 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.